FindTrial
Sign In

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00463437
Enrollment
1437
Registered
2007-04-20
Start date
2007-04-25
Completion date
2008-06-14
Last updated
2020-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Acellular Pertussis, Tetanus, Poliomyelitis, Diphtheria, Streptococcus Pneumoniae Vaccines

Keywords

Fever., Meningococcal disease., Pneumococcal disease., Meningococcal vaccine., Pneumococcal vaccine., Immunogenicity., Booster vaccination., Safety.

Brief summary

The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK1024850A at 11 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined and meningococcal serogroup C (MenC) or combined meningococcal serogroup C and Haemophilus influenzae type b (Hib-MenC) vaccine. This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00334334).

Detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Interventions

BIOLOGICALPneumococcal conjugate vaccine GSK1024850A

Intramuscular injection, 1 dose.

BIOLOGICALPrevenar

Intramuscular injection, 1 dose.

BIOLOGICALInfanrix hexa

Intramuscular injection, 1 dose. In Germany and Poland.

BIOLOGICALInfanrix IPV Hib

Intramuscular injection, 1 dose. In Spain.

BIOLOGICALInfanrix penta

Intramuscular injection, 1 dose. In Germany and Poland.

BIOLOGICALInfanrix IPV

Intramuscular injection, 1 dose. In Spain.

BIOLOGICALMeningitec

Intramuscular injection, 1 dose.

BIOLOGICALNeisVac-C

Intramuscular injection, 1 dose.

BIOLOGICALMenitorix

Intramuscular injection, 1 dose.

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
11 Months to 18 Months
Healthy volunteers
Yes

Inclusion criteria

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. * A male or female between, and including, 11-18 months of age at the time of the booster vaccination. * A male or female who previously participated in study 107005 and received three doses of pneumococcal conjugate vaccine. * Written informed consent obtained from the parent or guardian of the subject. * Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion criteria

* Concurrently participating in another clinical study, at any time during the study period (active phase and extended safety follow-up), in which the subject has been or will be exposed to an investigational or a non-investigational product. * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within one month preceding the booster dose of study vaccines, or planned use during the entire study period * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the booster dose of study vaccines. * Planned administration/administration of a vaccine not foreseen by the study protocol, during the period starting one month before the booster dose of study vaccines and up to the follow-up visit (one month after the booster dose of study vaccines). * Administration of any pneumococcal, diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, MenC and/or Hib-MenC vaccines other than the study vaccines from study 107005. * History of, or intercurrent, diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, meningococcal serogroup C disease. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. * History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or progressive neurological disease. * Acute disease at the time of enrolment. * Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination. * A family history of congenital or hereditary immunodeficiency. * Major congenital defects or serious chronic illness. * Administration of immunoglobulins and/or any blood products within three months preceding the booster dose of study vaccines or planned administration during the active phase of the study (starting with the administration of the booster dose of study vaccines up to the follow-up visit one month after).

Design outcomes

Primary

MeasureTime frameDescription
Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)During the 4-day (Day 0-3) period after the booster vaccinationFever was measured as rectal temperature.

Secondary

MeasureTime frameDescription
Number of Subjects Reporting Solicited General SymptomsDuring the 4-day (Day 0-3) period after the booster vaccinationSolicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.
Number of Subjects Reporting Unsolicited Adverse Events (AE)During the 31-day (Day 0-30) period after the booster vaccinationAn AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Number of Subjects Reporting Serious Adverse Events (SAE)During the 31-day (Day 0-30) period after the booster vaccinationAn SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueBefore (pre) and one month after (post) the booster administrationAnti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueBefore (pre) and one month after (post) the booster administrationCut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.
Number of Subjects Reporting Solicited Local SymptomsDuring the 4-day (Day 0-3) period after the booster vaccinationSolicited local symptoms assessed include pain, redness and swelling.
Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueBefore (pre) and one month after (post) the booster administrationAnti-pneumococcal antibody cut-off value assessed was ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValueBefore (pre) and one month after (post) the booster administrationAnti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValueBefore (pre) and one month after (post) the booster administrationMeningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.
Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValueBefore (pre) and one month after (post) the booster administrationAnti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.
Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValueBefore (pre) and one month after (post) the booster administrationAnti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.
Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueBefore (pre) and one month after (post) the booster administrationAnti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

Countries

Germany, Poland, Spain

Participant flow

Participants by arm

ArmCount
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™
Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
359
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™
Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
363
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™
Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
358
Prevenar™ + Menitorix™
Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
357
Total1,437

Baseline characteristics

CharacteristicGSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Prevenar™ + Menitorix™Total
Age, Continuous14.3 Months
STANDARD_DEVIATION 1.81
14.3 Months
STANDARD_DEVIATION 1.74
14.3 Months
STANDARD_DEVIATION 1.78
14.3 Months
STANDARD_DEVIATION 1.78
14.3 Months
STANDARD_DEVIATION 1.78
Sex: Female, Male
Female
182 Participants176 Participants195 Participants171 Participants724 Participants
Sex: Female, Male
Male
177 Participants187 Participants163 Participants186 Participants713 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
297 / 359303 / 363302 / 358287 / 357
serious
Total, serious adverse events
15 / —9 / —13 / —13 / —

Outcome results

Primary

Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)

Fever was measured as rectal temperature.

Time frame: During the 4-day (Day 0-3) period after the booster vaccination

Population: Analysis was performed on the Total vaccinated cohort from Pn-HibC and Pr-HibC Groups on subjects for whom data were available.

ArmMeasureValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)11 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Fever Above 39.0 Degree Celsius (°C)8 subjects
Secondary

Number of Subjects Reporting Serious Adverse Events (SAE)

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

Time frame: From the beginning of the study up to the end of the extended 6-month safety follow-up period

ArmMeasureValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Serious Adverse Events (SAE)15 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Serious Adverse Events (SAE)9 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Serious Adverse Events (SAE)13 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Serious Adverse Events (SAE)13 subjects
Secondary

Number of Subjects Reporting Serious Adverse Events (SAE)

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

Time frame: During the 31-day (Day 0-30) period after the booster vaccination

ArmMeasureValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Serious Adverse Events (SAE)3 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Serious Adverse Events (SAE)5 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Serious Adverse Events (SAE)3 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Serious Adverse Events (SAE)2 subjects
Secondary

Number of Subjects Reporting Solicited General Symptoms

Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.

Time frame: During the 4-day (Day 0-3) period after the booster vaccination

Population: Subjects from the Total Vaccinated cohort for whom data were available.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Solicited General SymptomsDrowsiness124 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Solicited General SymptomsFever (≥ 38.0 °C)109 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Solicited General SymptomsIrritability170 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Solicited General SymptomsLoss of appetite101 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Solicited General SymptomsFever (≥ 38.0 °C)122 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Solicited General SymptomsIrritability190 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Solicited General SymptomsLoss of appetite99 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Solicited General SymptomsDrowsiness142 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Solicited General SymptomsIrritability191 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Solicited General SymptomsFever (≥ 38.0 °C)105 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Solicited General SymptomsLoss of appetite112 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Solicited General SymptomsDrowsiness139 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Solicited General SymptomsLoss of appetite93 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Solicited General SymptomsFever (≥ 38.0 °C)108 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Solicited General SymptomsDrowsiness105 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Solicited General SymptomsIrritability157 subjects
Secondary

Number of Subjects Reporting Solicited Local Symptoms

Solicited local symptoms assessed include pain, redness and swelling.

Time frame: During the 4-day (Day 0-3) period after the booster vaccination

Population: Subjects from the Total Vaccinated cohort for whom data were available.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Solicited Local SymptomsPain196 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Solicited Local SymptomsSwelling162 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Solicited Local SymptomsRedness194 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Solicited Local SymptomsPain195 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Solicited Local SymptomsSwelling148 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Solicited Local SymptomsRedness183 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Solicited Local SymptomsRedness186 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Solicited Local SymptomsPain193 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Solicited Local SymptomsSwelling150 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Solicited Local SymptomsPain165 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Solicited Local SymptomsSwelling134 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Solicited Local SymptomsRedness173 subjects
Secondary

Number of Subjects Reporting Unsolicited Adverse Events (AE)

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame: During the 31-day (Day 0-30) period after the booster vaccination

ArmMeasureValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects Reporting Unsolicited Adverse Events (AE)59 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects Reporting Unsolicited Adverse Events (AE)74 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects Reporting Unsolicited Adverse Events (AE)59 subjects
Prevenar™ + Menitorix™Number of Subjects Reporting Unsolicited Adverse Events (AE)76 subjects
Secondary

Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off Value

Anti-meningococcal polysaccharide C antibody cut-off value assessed was ≥ 0.3 µg/mL.

Time frame: Before (pre) and one month after (post) the booster administration

Population: Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValuePre (n=126,124,125,135)95 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValuePost (n=156,149,159,149)156 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValuePost (n=156,149,159,149)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValuePre (n=126,124,125,135)82 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValuePre (n=126,124,125,135)105 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValuePost (n=156,149,159,149)159 subjects
Prevenar™ + Menitorix™Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValuePre (n=126,124,125,135)102 subjects
Prevenar™ + Menitorix™Number of Subjects With Anti-meningococcal Polysaccharide C Antibody Concentrations Above the Cut-off ValuePost (n=156,149,159,149)149 subjects
Secondary

Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off Value

Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was ≥ 0.15 µg/mL.

Time frame: Before (pre) and one month after (post) the booster administration

Population: Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValuePre (n=147,144,150,148)122 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValuePost (n=157,153,160,152)157 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValuePre (n=147,144,150,148)128 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValuePost (n=157,153,160,152)153 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValuePost (n=157,153,160,152)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValuePre (n=147,144,150,148)145 subjects
Prevenar™ + Menitorix™Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValuePre (n=147,144,150,148)143 subjects
Prevenar™ + Menitorix™Number of Subjects With Anti-polyribosyl-ribitol Phosphate Antibody Concentrations Above the Cut-off ValuePost (n=157,153,160,152)152 subjects
Secondary

Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off Value

Anti-protein D antibody cut-off value assessed was ≥ 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).

Time frame: Before (pre) and one month after (post) the booster administration

Population: Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValuePre (n=147,153,147,146)144 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValuePost (n=158,152,160,148)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValuePost (n=158,152,160,148)151 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValuePre (n=147,153,147,146)147 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValuePre (n=147,153,147,146)138 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValuePost (n=158,152,160,148)160 subjects
Prevenar™ + Menitorix™Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValuePre (n=147,153,147,146)59 subjects
Prevenar™ + Menitorix™Number of Subjects With Anti-protein D Antibody Concentrations Above the Cut-off ValuePost (n=158,152,160,148)66 subjects
Secondary

Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value

Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

Time frame: Before (pre) and one month after (post) the booster administration

Population: Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6A pre (n=145,144,144,149)126 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6A post (n=156,152,159,152)152 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19A pre (n=145,153,145,151)130 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19A post (n=157,153,160,152)154 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6A post (n=156,152,159,152)145 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19A pre (n=145,153,145,151)138 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19A post (n=157,153,160,152)151 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6A pre (n=145,144,144,149)120 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19A pre (n=145,153,145,151)121 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6A post (n=156,152,159,152)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19A post (n=157,153,160,152)155 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6A pre (n=145,144,144,149)119 subjects
Prevenar™ + Menitorix™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19A post (n=157,153,160,152)149 subjects
Prevenar™ + Menitorix™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6A post (n=156,152,159,152)148 subjects
Prevenar™ + Menitorix™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6A pre (n=145,144,144,149)110 subjects
Prevenar™ + Menitorix™Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19A pre (n=145,153,145,151)87 subjects
Secondary

Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off Value

Meningococcal serogroup C serum bactericidal assay titer cut-off value assessed was ≥ 8.

Time frame: Before (pre) and one month after (post) the booster administration

Population: Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValuePre (n=68,65,66,78)57 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValuePost (n=89,84,79,76)89 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValuePost (n=89,84,79,76)84 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValuePre (n=68,65,66,78)62 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValuePre (n=68,65,66,78)62 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValuePost (n=89,84,79,76)79 subjects
Prevenar™ + Menitorix™Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValuePre (n=68,65,66,78)68 subjects
Prevenar™ + Menitorix™Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Titer Above the Cut-off ValuePost (n=89,84,79,76)76 subjects
Secondary

Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off Value

Anti-pneumococcal antibody cut-off value assessed was ≥ 8. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.

Time frame: Before (pre) and one month after (post) the booster administration

Population: Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-6A pre (n=108,110,106,110)68 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-6A post (n=127,128,128,122)116 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-19A pre (n=133,138,136,134)4 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-19A post (n=124,132,130,123)77 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-6A post (n=127,128,128,122)119 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-19A pre (n=133,138,136,134)11 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-19A post (n=124,132,130,123)75 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-6A pre (n=108,110,106,110)66 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-19A pre (n=133,138,136,134)4 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-6A post (n=127,128,128,122)117 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-19A post (n=124,132,130,123)50 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-6A pre (n=108,110,106,110)73 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-19A post (n=124,132,130,123)29 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-6A post (n=127,128,128,122)119 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-6A pre (n=108,110,106,110)62 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes Above the Cut-off ValueOpsono-19A pre (n=133,138,136,134)2 subjects
Secondary

Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off Value

Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was ≥ 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F.

Time frame: Before (pre) and one month after (post) the booster administration

Population: Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-9V pre (n=133,133,130,130)131 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-9V post (n=143,139,143,137)143 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-4 post (n=137,134,140,135)137 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-18C pre (n=126,118,123,123)45 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-14 pre (n=121,125,114,125)115 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-1 pre (n=144,145,141,143)46 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-14 post (n=137,138,138,134)137 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-1 post (n=140,139,140,137)132 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-23F pre (n=132,136,128,137)121 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-5 pre (n=116,114,117,124)77 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-5 post (n=124,130,136,127)121 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-19F post (n=137,137,139,133)133 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-6B pre (n=133,132,133,137)75 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-23F post (n=145,143,146,143)145 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-6B post (n=142,135,142,140)134 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-4 pre (n=104,121,112,109)61 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-19F pre (n=127,135,134,134)102 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-7F pre (n=111,122,115,104)109 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-7F post (n=140,137,139,112)140 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-18C post (n=121,129,121,114)121 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-5 post (n=124,130,136,127)127 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-9V pre (n=133,133,130,130)130 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-23F pre (n=132,136,128,137)120 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-18C pre (n=126,118,123,123)54 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-1 pre (n=144,145,141,143)39 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-9V post (n=143,139,143,137)139 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-23F post (n=145,143,146,143)143 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-7F post (n=140,137,139,112)137 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-5 pre (n=116,114,117,124)71 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-14 pre (n=121,125,114,125)116 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-6B pre (n=133,132,133,137)60 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-14 post (n=137,138,138,134)138 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-7F pre (n=111,122,115,104)117 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-4 post (n=137,134,140,135)134 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-19F pre (n=127,135,134,134)110 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-4 pre (n=104,121,112,109)67 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-6B post (n=142,135,142,140)127 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-1 post (n=140,139,140,137)133 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-19F post (n=137,137,139,133)132 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-18C post (n=121,129,121,114)127 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-14 pre (n=121,125,114,125)107 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-1 pre (n=144,145,141,143)41 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-1 post (n=140,139,140,137)127 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-4 pre (n=104,121,112,109)61 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-4 post (n=137,134,140,135)140 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-5 pre (n=116,114,117,124)72 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-5 post (n=124,130,136,127)131 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-6B pre (n=133,132,133,137)75 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-6B post (n=142,135,142,140)135 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-7F pre (n=111,122,115,104)109 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-7F post (n=140,137,139,112)139 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-9V pre (n=133,133,130,130)122 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-9V post (n=143,139,143,137)143 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-14 post (n=137,138,138,134)138 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-18C pre (n=126,118,123,123)34 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-18C post (n=121,129,121,114)121 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-19F pre (n=127,135,134,134)95 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-19F post (n=137,137,139,133)139 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-23F pre (n=132,136,128,137)105 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-23F post (n=145,143,146,143)146 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-7F post (n=140,137,139,112)53 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-7F pre (n=111,122,115,104)42 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-23F pre (n=132,136,128,137)124 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-18C post (n=121,129,121,114)110 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-6B post (n=142,135,142,140)138 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-6B pre (n=133,132,133,137)67 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-1 post (n=140,139,140,137)12 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-19F pre (n=127,135,134,134)29 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-5 post (n=124,130,136,127)4 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-5 pre (n=116,114,117,124)3 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-1 pre (n=144,145,141,143)8 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-19F post (n=137,137,139,133)131 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-4 post (n=137,134,140,135)135 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-14 pre (n=121,125,114,125)124 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-4 pre (n=104,121,112,109)73 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-14 post (n=137,138,138,134)134 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-9V post (n=143,139,143,137)137 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-9V pre (n=133,133,130,130)126 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-23F post (n=145,143,146,143)143 subjects
Prevenar™ + Menitorix™Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-off ValueOpsono-18C pre (n=126,118,123,123)35 subjects
Secondary

Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off Value

Anti-pneumococcal antibody concentration cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

Time frame: Before (pre) and one month after (post) the booster administration

Population: Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.

ArmMeasureGroupValue (NUMBER)
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-18C post (n=157,152,160,152)157 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-9V post (n=158,153,160,153)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-4 post (n=158,153,160,152)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-18C pre (n=151,153,145,151)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-14 pre (n=153,158,152,153)151 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-1 pre (n=150,152,149, 151)146 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-14 post (n=158,153,160,153)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-1 post (n=158,152,160,151)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-23F pre (n=152,156,150,153)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-5 pre (n=149,146,146,148)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-5 post (n=157,153,160,150)157 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19F post (n=158,151,160,152)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6B pre (n=151,155,150,151)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-23F post (n=158,153,160,153)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6B post (n=158,153,160,153)157 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-4 pre (n=153,156,150,153)152 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19F pre (n=143,146,139,150)143 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-7F pre (n=149,153,148,151)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-7F post (n=158,152,160,151)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-9V pre (n=149,155,149,152)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-18C post (n=157,152,160,152)152 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-9V pre (n=149,155,149,152)154 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-23F pre (n=152,156,150,153)153 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-18C pre (n=151,153,145,151)151 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-5 post (n=157,153,160,150)153 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-9V post (n=158,153,160,153)152 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-1 pre (n=150,152,149, 151)146 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-23F post (n=158,153,160,153)152 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-7F post (n=158,152,160,151)152 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-14 pre (n=153,158,152,153)157 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6B pre (n=151,155,150,151)153 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-14 post (n=158,153,160,153)153 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-7F pre (n=149,153,148,151)153 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-4 post (n=158,153,160,152)153 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19F pre (n=143,146,139,150)146 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-4 pre (n=153,156,150,153)156 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6B post (n=158,153,160,153)151 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-5 pre (n=149,146,146,148)146 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-1 post (n=158,152,160,151)152 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19F post (n=158,151,160,152)151 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-14 pre (n=153,158,152,153)152 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-1 pre (n=150,152,149, 151)140 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-1 post (n=158,152,160,151)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-4 pre (n=153,156,150,153)147 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-4 post (n=158,153,160,152)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-5 pre (n=149,146,146,148)144 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-5 post (n=157,153,160,150)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6B pre (n=151,155,150,151)144 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6B post (n=158,153,160,153)158 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-7F pre (n=149,153,148,151)147 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-7F post (n=158,152,160,151)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-9V pre (n=149,155,149,152)149 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-9V post (n=158,153,160,153)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-14 post (n=158,153,160,153)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-18C pre (n=151,153,145,151)145 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-18C post (n=157,152,160,152)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19F pre (n=143,146,139,150)139 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19F post (n=158,151,160,152)160 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-23F pre (n=152,156,150,153)144 subjects
GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-23F post (n=158,153,160,153)158 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-7F post (n=158,152,160,151)25 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-7F pre (n=149,153,148,151)18 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-23F pre (n=152,156,150,153)141 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-18C post (n=157,152,160,152)152 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6B post (n=158,153,160,153)153 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-6B pre (n=151,155,150,151)137 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-1 post (n=158,152,160,151)28 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19F pre (n=143,146,139,150)143 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-5 post (n=157,153,160,150)64 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-5 pre (n=149,146,146,148)37 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-1 pre (n=150,152,149, 151)21 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-19F post (n=158,151,160,152)152 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-4 post (n=158,153,160,152)152 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-14 pre (n=153,158,152,153)151 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-4 pre (n=153,156,150,153)150 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-14 post (n=158,153,160,153)153 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-9V post (n=158,153,160,153)153 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-9V pre (n=149,155,149,152)152 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-23F post (n=158,153,160,153)153 subjects
Prevenar™ + Menitorix™Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-off ValueAnti-18C pre (n=151,153,145,151)151 subjects

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026